Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 10/20 | 0.69 |
| ▸ | ACE | P12821 | 6/20 | 0.67 |
| ▸ | CPA1 | P15085 | 6/20 | 0.67 |
| ▸ | ACE2 | Q9BYF1 | 6/20 | 0.67 |
| ▸ | MMP2 | P08253 | 1/20 | 0.60 |
| ▸ | MMP7 | P09237 | 1/20 | 0.60 |
| ▸ | MMP9 | P14780 | 1/20 | 0.60 |
| ▸ | MMP12 | P39900 | 1/20 | 0.60 |
| ▸ | MMP13 | P45452 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8510050 | 1.00 | MME (0.69) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL12864507 | 1.00 | MME (0.69) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL7901163 | 0.92 | MME (0.78) | MMEACECPA1ACE2 | |
| SCHEMBL15692372 | 0.91 | MME (0.67) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL15649671 | 0.91 | MME (0.67) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL23361048 | 0.88 | MME (0.67) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL11341642 | 0.88 | MME (0.67) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL11341637 | 0.88 | MME (0.67) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL6380775 | 0.88 | MME (0.67) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL12781768 | 0.88 | MME (0.67) | MMEACECPA1ACE2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135810-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED TETRAHYDRO BETA-CARBOLINES | PTC THERAPEUTICS INC (US) | 2019-05-09 | — | — | US | claimed |
| US-20120136154-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED TETRAHYDRO BETA-CARBOLINES | PTC THERAPEUTICS, INC. | 2012-05-31 | — | — | US | claimed |
| US-20210155771-A1 | PLASTICIZER AND PLASTIC PRODUCT | LARGAN MEDICAL CO., LTD. (TW) | 2021-05-27 | — | — | US | disclosed |
| US-10947231-B2 | Processes for the preparation of substituted tetrahydro beta-carbolines | PTC THERAPEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20190135810-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED TETRAHYDRO BETA-CARBOLINES | PTC THERAPEUTICS INC (US) | 2019-05-09 | — | — | US | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20170143835-A1 | SUBSTITUTED ANIONIC COMPOUNDS CONSISTING OF A BACKBONE MADE UP OF A DISCRETE NUMBER OF SACCHARIDE UNITS | ADOCIA (FR) | 2017-05-25 | — | — | US | disclosed |
| US-20170143835-A1 | SUBSTITUTED ANIONIC COMPOUNDS CONSISTING OF A BACKBONE MADE UP OF A DISCRETE NUMBER OF SACCHARIDE UNITS | ADOCIA (FR) | 2017-05-25 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| US-20140187499-A1 | SUBSTITUTED ANIONIC COMPOUNDS CONSISTING OF A BACKBONE MADE UP OF A DISCRETE NUMBER OF SACCHARIDE UNITS | ADOCIA (FR) | 2014-07-03 | — | — | US | disclosed |
| US-20140187499-A1 | SUBSTITUTED ANIONIC COMPOUNDS CONSISTING OF A BACKBONE MADE UP OF A DISCRETE NUMBER OF SACCHARIDE UNITS | ADOCIA (FR) | 2014-07-03 | — | — | US | disclosed |
| US-20120136154-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED TETRAHYDRO BETA-CARBOLINES | PTC THERAPEUTICS, INC. | 2012-05-31 | — | — | US | disclosed |
| WO-1996000391-A1 | METHODS FOR THE SYNTHESIS OF DIKETOPIPERAZINES | AFFYMAX TECHNOLOGIES N.V. (AN) | 1996-01-04 | — | — | WO | disclosed |
| EP-0178911-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1992-01-22 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0178911-A2 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1986-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | MME 49/4885ACE 80/4885CPA1 1243/4885 |
| US-10947231-B2 | Processes for the preparation of substituted tetrahydro beta-carbolines | TPH1, TPH2, HTR1B | MME 3865/4885ACE 1976/4885CPA1 2118/4885 |
| US-20170143835-A1 | SUBSTITUTED ANIONIC COMPOUNDS CONSISTING OF A BACKBONE MADE UP OF A DISCRETE NUMBER OF SACCHARIDE UNITS | ALG8, FUT8, UGT8 | MME 896/4885ACE 540/4885CPA1 807/4885 |
| US-20140187499-A1 | SUBSTITUTED ANIONIC COMPOUNDS CONSISTING OF A BACKBONE MADE UP OF A DISCRETE NUMBER OF SACCHARIDE UNITS | FUT6, FUT5, FUT8 | MME 427/4885ACE 609/4885CPA1 355/4885 |
| US-20120136154-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED TETRAHYDRO BETA-CARBOLINES | TPH1, TPH2, HTR1B | MME 3874/4885ACE 1877/4885CPA1 2155/4885 |
| US-20190135810-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED TETRAHYDRO BETA-CARBOLINES | TPH1, TPH2, HTR1B | MME 3865/4885ACE 1976/4885CPA1 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.